Verastem Inc (VSTM) 7.93 $VSTM
Verastem PI3K inhibitor an Orphan Drug for mesothelioma
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:55AM CST
VSTM: 7.93 (-0.44)
Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
Business Wire - Thu Feb 12, 6:01AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
VSTM: 7.93 (-0.44)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Verastem Announces the Grant of Inducement Awards
Business Wire - Thu Feb 05, 6:02AM CST
Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that on February 2, 2015, the Company granted stock options to seven new employees to purchase an aggregate of 210,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Verastem pursuant to NASDAQ Listing Rule 5635(c)(4).
VSTM: 7.93 (-0.44)
Verastem to Present at Upcoming Investor Conferences
Business Wire - Tue Feb 03, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the following upcoming investor conferences:
VSTM: 7.93 (-0.44)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
Christoph H. Westphal of Verastem, Inc. (VSTM)-NasdaqGM bought Shares of VSTM
M2 - Fri Jan 30, 11:42PM CST
Reported by InsiderCow.com at 2015-01-28 14:17:28 ET
VSTM: 7.93 (-0.44)
3 Biotech Stocks You Won't Want To Miss In 2015
BPD Research - at Seeking Alpha - Fri Jan 30, 10:30AM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), STML: 14.07 (-0.10)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 4.60 (+0.44), RNST: 27.87 (+0.28), ASPX: 65.76 (+2.76), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), SNI: 73.00 (+0.39), ADBE: 76.51 (+1.92), VSTM: 7.93 (-0.44), ALDR: 26.06 (+0.18), ALNY: 95.54 (+1.67), SSP: 20.91 (+0.47), SGNT: 27.75 (-0.41), MA: 87.14 (-0.38), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59), SCHW: 29.13 (-0.83)
The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M
at The Street - Thu Jan 29, 6:44AM CST
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.
VSTM: 7.93 (-0.44), FLKS: 13.89 (-0.18)
Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Business Wire - Thu Jan 29, 6:00AM CST
Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Verastem to 8,337,500 shares and increased the total gross proceeds raised in this offering to $54.2 million, before deducting the underwriting discounts and commissions. The net proceeds to Verastem from this offering were $50.9 million.
VSTM: 7.93 (-0.44)
Recent Offering Provides Great Opportunity To Buy Verastem Before Significant 2015 Catalysts
BPD Research - at Seeking Alpha - Wed Jan 28, 6:25PM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30)
Verastem Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Jan 22, 7:43PM CST
Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock, offered at a price of $6.50 per share to the public. The net proceeds to Verastem from this offering are expected to be approximately $44.1 million, after deducting underwriting discounts and commissions and offering expenses. All of the shares sold in the offering will be sold by Verastem. The offering is expected to close on or about January 28, 2015, subject to the satisfaction of customary closing conditions. Verastem has granted to the underwriters a 30-day option to purchase up to 1,087,500 additional shares of common stock. Verastem anticipates using the net proceeds from the offering for: its registration-directed COMMAND study in mesothelioma and the initiation of associated studies in preparation for a possible NDA filing to the FDA and similar filings to other regulatory authorities; its other ongoing clinical trials with VS-6063, VS-4718 and VS-5584; and the balance, if any, for other general corporate purposes.
VSTM: 7.93 (-0.44)
Verastem Announces Proposed Public Offering of Common Stock
Business Wire - Tue Jan 20, 3:01PM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it intends to offer and sell $40 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering are to be sold by Verastem.
VSTM: 7.93 (-0.44)
Verastem mesothelioma drug candidate an Orphan Drug in EU
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 10:30AM CST
VSTM: 7.93 (-0.44)
Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
Business Wire - Tue Jan 20, 7:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
VSTM: 7.93 (-0.44)
Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma
Business Wire - Tue Jan 20, 6:00AM CST
---Synergistic Activity of VS-6063 and VS-5584 Demonstrated in Preclinical Models of Mesothelioma-
VSTM: 7.93 (-0.44)
Verastem Announces Publication of Scientific Data for VS-5584 in Cancer Research
Business Wire - Fri Jan 16, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a paper, titled "PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells," has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research (AACR).
VSTM: 7.93 (-0.44)
Verastem Provides Year-End 2014 Update and Outlook for 2015
Business Wire - Thu Jan 08, 3:01PM CST
---Signals of Clinical Activity in all Programs Targeting Cancer Stem Cells Have Been Observed-
VSTM: 7.93 (-0.44), INCY: 75.94 (+0.28)
Verastem to review progress in 2014 and present outlook for 2015
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 3:43PM CST
VSTM: 7.93 (-0.44)
Verastem PI3K inhibitor an Orphan Drug for mesothelioma
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 7:55AM CST
VSTM: 7.93 (-0.44)
Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
Business Wire - Thu Feb 12, 6:01AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
VSTM: 7.93 (-0.44)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Verastem Announces the Grant of Inducement Awards
Business Wire - Thu Feb 05, 6:02AM CST
Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that on February 2, 2015, the Company granted stock options to seven new employees to purchase an aggregate of 210,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Verastem pursuant to NASDAQ Listing Rule 5635(c)(4).
VSTM: 7.93 (-0.44)
Verastem to Present at Upcoming Investor Conferences
Business Wire - Tue Feb 03, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the following upcoming investor conferences:
VSTM: 7.93 (-0.44)
Did Researchers Just Discover the Cause of Pancreatic Cancer?
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 31, 11:23AM CST
Source: Flickr user Sunil Joshi. Although no cancer diagnosis is welcome, perhaps no cancer type comes with a more frightening outlook than pancreatic cancer. According to data from the American Cancer Society, pancreatic cancer is the twelfth...
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), PFE: 34.64 (-0.23), NLNK: 38.84 (+1.51), THLD: 4.03 (+0.21), CELG: 115.88 (+0.16)
Christoph H. Westphal of Verastem, Inc. (VSTM)-NasdaqGM bought Shares of VSTM
M2 - Fri Jan 30, 11:42PM CST
Reported by InsiderCow.com at 2015-01-28 14:17:28 ET
VSTM: 7.93 (-0.44)
3 Biotech Stocks You Won't Want To Miss In 2015
BPD Research - at Seeking Alpha - Fri Jan 30, 10:30AM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30), STML: 14.07 (-0.10)
InsiderInsights.com Daily Round Up 1/28/15: FDO, WIA, EFOI, ASPX
InsiderInsights - at Seeking Alpha - Thu Jan 29, 9:39AM CST
EFOI: 4.60 (+0.44), RNST: 27.87 (+0.28), ASPX: 65.76 (+2.76), FDO: 77.86 (+0.31), SHLD: 35.70 (+2.32), SNI: 73.00 (+0.39), ADBE: 76.51 (+1.92), VSTM: 7.93 (-0.44), ALDR: 26.06 (+0.18), ALNY: 95.54 (+1.67), SSP: 20.91 (+0.47), SGNT: 27.75 (-0.41), MA: 87.14 (-0.38), WIA: 11.49 (-0.03), CRM: 62.85 (+1.59), SCHW: 29.13 (-0.83)
The Absurdity of Flex Pharma IPO: 2 Spices and a Veg Net $86M
at The Street - Thu Jan 29, 6:44AM CST
If the biotech bull market hasn't reached 11 on the absurdity meter quite yet, the Flex Pharma FLKS IPO gets us close.
VSTM: 7.93 (-0.44), FLKS: 13.89 (-0.18)
Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Business Wire - Thu Jan 29, 6:00AM CST
Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Verastem to 8,337,500 shares and increased the total gross proceeds raised in this offering to $54.2 million, before deducting the underwriting discounts and commissions. The net proceeds to Verastem from this offering were $50.9 million.
VSTM: 7.93 (-0.44)
Recent Offering Provides Great Opportunity To Buy Verastem Before Significant 2015 Catalysts
BPD Research - at Seeking Alpha - Wed Jan 28, 6:25PM CST
VSTM: 7.93 (-0.44), OMED: 26.06 (+0.30)
Verastem Announces Pricing of Public Offering of Common Stock
Business Wire - Thu Jan 22, 7:43PM CST
Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock, offered at a price of $6.50 per share to the public. The net proceeds to Verastem from this offering are expected to be approximately $44.1 million, after deducting underwriting discounts and commissions and offering expenses. All of the shares sold in the offering will be sold by Verastem. The offering is expected to close on or about January 28, 2015, subject to the satisfaction of customary closing conditions. Verastem has granted to the underwriters a 30-day option to purchase up to 1,087,500 additional shares of common stock. Verastem anticipates using the net proceeds from the offering for: its registration-directed COMMAND study in mesothelioma and the initiation of associated studies in preparation for a possible NDA filing to the FDA and similar filings to other regulatory authorities; its other ongoing clinical trials with VS-6063, VS-4718 and VS-5584; and the balance, if any, for other general corporate purposes.
VSTM: 7.93 (-0.44)
Verastem Announces Proposed Public Offering of Common Stock
Business Wire - Tue Jan 20, 3:01PM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it intends to offer and sell $40 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares to be sold in the offering are to be sold by Verastem.
VSTM: 7.93 (-0.44)
Verastem mesothelioma drug candidate an Orphan Drug in EU
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 10:30AM CST
VSTM: 7.93 (-0.44)
Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
Business Wire - Tue Jan 20, 7:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.
VSTM: 7.93 (-0.44)
Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma
Business Wire - Tue Jan 20, 6:00AM CST
---Synergistic Activity of VS-6063 and VS-5584 Demonstrated in Preclinical Models of Mesothelioma-
VSTM: 7.93 (-0.44)
Verastem Announces Publication of Scientific Data for VS-5584 in Cancer Research
Business Wire - Fri Jan 16, 6:00AM CST
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a paper, titled "PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells," has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research (AACR).
VSTM: 7.93 (-0.44)
Verastem Provides Year-End 2014 Update and Outlook for 2015
Business Wire - Thu Jan 08, 3:01PM CST
---Signals of Clinical Activity in all Programs Targeting Cancer Stem Cells Have Been Observed-
VSTM: 7.93 (-0.44), INCY: 75.94 (+0.28)
Verastem to review progress in 2014 and present outlook for 2015
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 3:43PM CST
VSTM: 7.93 (-0.44)
